Cone-Rod Dystrophy Sequencing Panel

Test Information

This panel of 37 genes is intended for patients with a diagnosis or clinical suspicion of Cone-Rod Dystrophy and is performed by Next Generation Sequencing (NGS). This molecular test is useful to confirm the diagnosis and to identify the disease causing mutations within a family to allow for carrier testing and prenatal diagnosis.

Turnaround Time

8 weeks

CPT Code(s)





  • ABCA4
  • ADAM9
  • AIPL1
  • ATF6
  • BEST1
  • C8orf37
  • CACNA2D4
  • CDHR1
  • CFAP410
  • CNGA3
  • CNGB3
  • CNNM4
  • CRB1
  • CRX
  • EYS
  • GNAT2
  • GUCA1A
  • GUCY2D
  • KCNV2
  • PDE6C
  • PDE6H
  • POC1B
  • PROM1
  • PRPH2
  • RAB28
  • RAX2
  • RDH5
  • RIMS1
  • RPGR
  • SEMA4A
  • TTLL5
  • TULP1
  • UNC119

Clinical Information

This panel consists of 37 genes that have been associated with cone-rody dystrophy and related disorders including achromatopsia, retinal cone dystrophy, Jalili syndrome and some forms of Leber congenital amaurosis. Cone-rod dystophy disorders demonstrate high genetic heterogeneity and can be inherited in an autosomal recessive, autosomal dominant, or X-linked manner.


Next Generation Sequencing


The current design of this panel covers all genes and the flanking intronic sequences. This method allows for analysis of greater than 98% of the targeted sequence for the detection of nucleotide substitutions and small deletions and duplications. Large deletions and duplications will not be detected by this panel. Mutations and variants identified on the panel are confirmed with Sanger sequencing. All novel and apparently pathogenic changes are reported when found within the coding region as well as within 10 basepairs of each intron/exon boundary for each gene. Promoter and 3' untranslated sequences are not included in the current analysis. It should be noted that the current protocol is not specifically designed to detect copy number alterations and single exon deletions may require additional follow-up to determine whether or not they represent technical artifacts. We recommend further array-based testing to more accurately address the concerns of dosage alterations. The Cytogenetic Laboratory at GGC offers a high resolution microarray to complement the sequencing panel. The GGC Diagnostic Laboratory Directors are available for further consultation regarding the limitations of the NGS and array testing procedures.

Specimen Requirements

The preferred sample type is peripheral blood collected in an EDTA (purple top) tube - at least 2-3ml for pediatric patients and 5-6ml for adult patients. Extracted DNA and saliva are also accepted for this test. Saliva samples must be submitted in an approved saliva kit. Contact the lab to receive a saliva kit or to have one sent to your patient.

Transport Instructions

The specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.

Prenatal Testing Information

If the pathogenic mutation(s) are identified in an affected individual using this panel, prenatal diagnosis is available for future pregnancies. Sanger sequencing will be used for prenatal diagnosis when there is a known familial mutation. Additional fees for cell culture and maternal cell contamination may apply. Maternal cell contamination studies are required for all prenatal molecular tests. Contact the laboratory prior to sending a prenatal specimen.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC

Lucy's Story

When our daughter Lucy had a metabolic crisis at 7 days old, we were shocked and devastated to find out that she was born with a rare genetic disorder (MSUD). Her newborn screening results did not make it back in time to prevent the crisis, and no one at our local hospital was familiar with the disease. They did not know how to treat her. Calls were made to Greenwood Genetic Center to confirm her diagnosis and guide her care. Dr. Champaigne and Ami...

In The News